Biotech Values

[DewDiligence]

CLVS’ PR contained subgroup analysis of previously released (aggregated) data, as you surmised. I doubt that these data will materially increase sales of Rubraca, but they are nevertheless meaningful results from a medical standpoint, IMO. It’s getting harder and harder for anyone to justify not using a PARP inhibitor in ovarian cancer first-line-maintenance, yet many oncologists are still doing that.